The stock has been in a pronounced downtrend over the past six months, with the price declining from approximately $353 in early October 2025 to around $270 by the end of March 2026, representing a 23.5% drop. This decline significantly underperformed the broader market, as indicated by a -20.68 relative strength over six months. Short-term performance has been weak, with the stock down 7.73% over the past month and 18.03% over the past three months, both periods showing substantial negative relative strength versus the S&P 500. The current price of $270.59 sits near the lower end of its 52-week range of $234.60 to $606.36, representing a decline of over 55% from its high. The stock has experienced a maximum drawdown of -60.34%, indicating severe volatility and selling pressure over the observed period. While the price rose 3.36% on the last trading day, this follows a significant multi-month decline.

Revenue growth remains robust on a year-over-year basis, with Q4 2025 revenue of $113.2 billion representing 12.31% growth compared to the prior year's Q4. However, profitability has deteriorated sharply in the most recent quarter, with Q4 2025 net income plummeting to $10 million (a net margin of 0.0088%) from $5.54 billion in Q4 2024, primarily due to a significant increase in other expenses and a large tax benefit reversal. The company maintains a moderate debt-to-equity ratio of 0.83, indicating manageable leverage. Cash flow generation remains a strength, with trailing twelve-month free cash flow of $16.08 billion, providing substantial financial flexibility for operations, dividends, and share repurchases despite the recent earnings pressure. Operational efficiency metrics have been impacted by the recent profit decline. Return on Equity (ROE) stands at 12.8%, which is respectable but has likely fallen from higher historical levels given the Q4 results. The current ratio of 0.79 suggests a relatively tight liquidity position for meeting short-term obligations.